TONSL

Across TCGA pan-cancer cohorts, TONSL Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TONSL data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher TONSL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TONSL expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

PAAD, LGG, and KICH are the cancer types where TONSL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
LGG	DFS	Median	All	0.156	0.834	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	OS	Median	IV	0.132	0.604	<.001	12	view →
HNSC	OS	Median	IV	0.118	0.733	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	1.000	0.215	.020	5	view →
LUAD	DFS	Median	All	0.213	0.676	.012	3	view →
UCEC	OS	Median	All	1.000	0.866	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TONSL–PAAD (OS)

Open the PAAD breakdown →